IBXXF
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.01 | $0 | -$2M |
| 2025 Q2 | -0.01 | $25,734 | -$2M |
| 2024 Q4 | -0.01 | $1M | -$1M |
| 2024 Q2 | -0.05 | $2M | -$156,938 |
| 2023 Q4 | -0.15 | $746,669 | -$2M |
| 2023 Q2 | -0.27 | $690,012 | -$6M |
| 2022 Q4 | -0.14 | $304,196 | -$4M |
| 2022 Q2 | -0.21 | $265,763 | -$5M |